Somatostatin as an Anti-Inflammatory Neuropeptide. From Physiological Basis to Drug Development

NeuroImmune Biology

Volumn 8, Issue C, 2009, Pages

  Pintér, Erika ^a   Helyes, Zsuzsanna ^a   Németh, József ^a   Szolcsányi, János ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957037445     PISSN: 15677443     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1567-7443(08)10406-9     Document Type: Review

References (81)

1. Krulich L., Dhariwal A.P.S., and McCann S.M. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinolology 83 (1968) 787-790
2. Brazeu P. Somatostatin: a peptide with unexpected physiologic activities. Am J Med 81 Suppl. 6B (1986) 8-13
3. Pradayrol L., Jornwall H., Mutt V., and Ribet A. N-terminally extended somatostatin: the primary structure of somatostatin-28. FEBS Lett 109 (1980) 55-58
4. Patel Y.C., Greenwood M.T., Panetta L., Demchyshyn L., Niznik H., and Srikant C.B. Minireview: the somatostatin receptor family. Life Sci 57 (1995) 1249-1265
5. Reisine T., and Bell G.I. Molecular properties of somatostatin receptors. Neuroscience 67 (1995) 777-790
6. Reichlin S. SRIF. New Engl J Med 309 (1983) 1495-1563
7. Schindler M., Holloway S., Hathway G., Wolf C.J., Humphrey P.P., and Emson P.C. Identification of somatostatin sst2(a) receptor expressing neurones in central regions involved in nociception. Brain Res 798 (1998) 25-35
8. Schally A.V. Oncological application of somatostatin analogues. Cancer Res 48 (1988) 6977-6985
9. Hoyer D., Bell G.I., Berelowitz M., Epelbaum J., Ferniuk W., Humphrey P.A., et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 16 (1995) 86-88
10. Hofland L.J., Visser-Wisselaar H.A., and Lamberts S.W.J. Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypes. Biochem Pharmacol 50 (1995) 287-297
11. Florio T., and Schettini G. Multiple intracellular effectors modulate physiological functions of the cloned somatostatin receptors. J Mol Endocrinol 17 (1996) 89-100
12. Patel Y.C. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 20 (1997) 348-367
13. Meyerhof W. The elucidation of somatostatin receptor functions: a current view. Rev Physiol Biochem Pharmacol 133 (1998) 55-108
14. Selmer I.S., Schindler M., Allen J.P., Humphrey P.P.A., and Emson P.C. Advances in understanding neuronal somatostatin receptors. Regul Pept 90 (2000) 1-18
15. Janecka A., Zubrzycka M., and Janecki T. Somatostatin analogs. J Pept Res 58 (2001) 91-107
16. ten Bokum A.M.C., Hofland L.J., and van Hagen P.M. Somatostatin and somatostatin receptors in the immune system: a review. Eur Cytokine Netw 11 (2000) 161-176
17. Jakobs K., Aktories K., and Schultz G. A nucleotide regulatory site for SRIF inhibition of adenylyl cyclase in S49 lymphoma cells. Nature 303 (1983) 177-178
18. Ikeda S., and Schofield G. SRIF blocks a ca++ current in rat sympathetic ganglion neurones. J Physiol 409 (1989) 221-240
19. Moore S., Madamba S., Joels M., and Siggins G. Somatostatin augments the M-current in hippocampal neurons. Science 239 (1988) 278-280
20. Mihara S., North R., and Suprenant A. SRIF increases and inwardly rectifying potassium conductance in guinea pig submucous plexus neurones. J Physiol 390 (1987) 335-355
21. Wang H., Bogen C., and Reisine Dichter T.M. SRIF-14 and SRIF-28 induce opposite effects on potassium currents in rat neocortical neurons. Proc Natl Acad Sci USA 86 (1989) 9616-9620
22. + exchange independent of cAMP. J Biol Chem 264 (1989) 21038-21042
23. Buscail L., Delesque N., Esteve J.P., Saint-Laurent N., Prats H., Clerc P., et al. Stimulation of tyrosine phosphatase and inhibition of cell proloferation by SRIF analogues: mediation by human SRIF receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 91 (1994) 2315-2319
24. Weinstock J.V. Production of neuropeptides by inflammatory cells within the granulomas of murine schistosomiasis mansoni. Eur J Clin Invest 21 (1991) 145-153
25. van Hagen P.M., Markusse H.M., Lamberts S.W., Kwekkeboom D.J., Reubi J.C., and Krenning E.P. Somatostatin receptor imaging. The presence of somatostatin receptors in rheumatoid arthritis. Arthritis Rheum 37 (1994) 1521-1527
26. Reubi J.C., Waser B., Markusse H.M., Krenning E.P., van Hagen M., and Laissue J.A. Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. Eur J Pharmacol 271 (1994) 371-378
27. Reubi J.C., Mazzucchelli L., and Laissue J.A. Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease. Gastroenterology 106 (1994) 951-959
28. van Hagen P.M., Krenning E.P., Kwekkeboom D.J., Reubi J.C., Anker-Lugtenburg P.J., Löwenberg B., et al. Somatostatin and the immune and haematopoetic system; a review. Eur J Clin Invest 24 (1994) 91-99
29. Sreeedharan S., Kodama K., Peterson K., and Goetzl E. Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem 264 (1989) 949-952
30. 5)enkephalinamide. Eur J Pharmacol 85 (1982) 171-176
31. Szolcsányi J., Pintér E., Helyes Oroszi G., and Németh J. Systemic anti-inflammatory effect induced by counter-irritation through a local release of somatostatin from nociceptors. Br J Pharmacol 125 (1998) 916-922
32. Helyes Z.s., Szabó Á., Németh J., Jakab B., Pintér E., Bánvölgyi Á., et al. Anti-inflammatory and analgesic effects of somatostatin released from capsaicin-sensitive sensory nerve terminals in Freund's adjuvant induced chronic arthritis model of the rat. Arthritis Rheum 50 (2004) 1677-1685
33. Helyes Z.s., Elekes K., Németh J., Pozsgai G., Sándor K., Kereskai L., et al. Role of transient receptor potential vanilloid 1 receptors in endotoxin-induced airway inflammation in the mouse. Am J Physiol Lung Cell Mol Physiol 292 5 (2007) L1173-L1181
34. Sicuteri F., Raino L., and Geppetti P. Substance P and endogenous opioids: how and where they could play a role in cluster headache. Cephalalgia 3 Suppl. 1 (1983) 143-145
35. Misery L. Skin, immunity and the nervous system. Br J Dermatol 137 (1997) 843-850
36. Elliott D.E., Li J., Blum A.M., Metwali A., Patel Y.C., and Weinstock J.V. SSTR2A is the dominant somatostatin receptor subtype by inflammatory cells, is widely expressed and directly regulates T cell IFN-γ release. Eur J Immunol 29 (1999) 2454-2463
37. Muscettola G., and Grasso G. Somatostatin and vasoactive intestinal peptide reduce interferon gamma production by human peripheral blood mononuclear cells. Immunobiology 180 (1990) 419-430
38. Blum A.M., Andrews P.V., Metwali A., Mathew R.C., Elliott D., and Weinstock J.V. Substance P and somatostatin can modulate the amount of IgG2a secreted in response to schistosome egg antigens in murine schistosomiasis mansoni. J Immunol 151 (1993) 6994-7004
39. Scicchitano R., Dazin P., Bienenstock J., Payan D.G., and Stanisz A.M. The murine IgA-secreting plasmacytoma MOPPC-315 expresses somatostatin receptors. J Immunol 141 (1988) 937-941
40. Eglezos A., Andrews P.V., and Helme R.D. In vivo inhibition of the rat primary antibody response to antigenic stimulation by somatostatin. Immunol Cell Biol 71 (1993) 125-129
41. Berman A.S., Chancellor-Freeland C., Zhu G., and Black P.H. Substance P primes murine peritoneal macrophages for an augmented pro-inflammatory cytokine response to lipopolysaccharide. Neuroimmunomodulation 3 (1996) 141-149
42. Niedermühl-Bichler M., and Wiedermann C.J. Suppression of superoxide release from human monocyte by somatostatin-related peptides. Regul Pept 41 (1992) 39-45
43. Wiedermann C.J., Reinisch N., and Braunsteiner H. Stimulation of monocyte chemotaxis by human growth hormone and its deactivation by somatostatin. Blood 82 (1993) 954-960
44. Kolasinski S.L., Haines K.A., Siegel E.L., Cronstein B.N., and Abramson S.B. Neuropeptides and inflammation. A somatostatin analog as a selective antagonist of neutrophil activation by substance P. Arthritis Rheum 35 (1992) 369-375
45. Chowers Y., Cahalon L., Lahav M., Schor H., Tal R., Bal-Meir S., et al. Somatostatin through its specific receptor inhibits spontaneous and TNF-α and bacteria-. Induced IL-8 and IL-1β secretion from intestinal epithelial cells. J Immunol 165 (2000) 2955-2961
46. Pintér E., Helyes Z.s., and Szolcsányi J. Inhibitory effect of somatostatin on inflammation and nociception. Pharmacol Ther 112 (2006) 440-456
47. Jancsó M., Jancsó-Gábor A., and Szolcsányi J. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol 31 (1967) 138-151
48. Bayliss W.M. The Vaso-Motor System (1923), Longmans, Green and Co, London
49. Lewis T. The Blood Vessels of the Human Skin and their Responses (1927), Shaw, London
50. Maggi C.A. Tachykinins and calcitonin gene-related peptide (CGRP) as co-transmitters released from peripheral endings of sensory nerves. Prog Neurobiol 45 (1995) 1-98
51. Lundberg J.M. Pharmacology and co-transmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Pharmacol Rev 48 (1996) 113-178
52. Pintér E., and Szolcsányi J. Inflammatory and anti-inflammatory effects of antidromic stimulation of dorsal roots in the rat. Agents Actions 25 (1988) 240-242
53. Pintér E., and Szolcsányi J. Systemic anti-inflammatory effect induced by antidromic stimulation of the dorsal roots in the rat. Neurosci Lett 212 (1996) 33-36
54. Winter C.A., Risley E.A., and Nuss G.W. Carrageenin-induced oedema in hind paw of the rat as an assay for anti-inflammatory drugs. Proc Soc Exp Biol Med 111 (1962) 544
55. Vinegar R.J., Truax F., and Selph J.L. Quantitative studies of the pathway to acute carrageenin inflammation. Fed Proc 35 (1976) 2447
56. Damas J., and Remacle-Volon G. Influence of a long-acting bradykinin antagonist, hoe 140, on some acute inflammatory reactions in the rat. Eur J Pharmacol (1992) 211 81
57. Cao T., Pintér E., Al-Rashed S., Gerard N., and Brain S.D. Neurokinin-1 receptor agonists are involved in mediating neutrophil accumulation in the inflamed, but normal cutaneous microvasculature: an in vivo study using neurokinin-1 receptor knockout mice. J Immunol 164 (2000) 5424-5429
58. Szolcsányi J., Helyes Oroszi G., Németh J., and Pintér E. Release of somatostatin and its role in the mediation of the anti-inflammatory effect induced by antidromic stimulation of sensory fibres of rat sciatic nerve. Br J Pharmacol 123 (1998) 936-942
59. Selye H. The Mast Cell (1965), Butterworths, Washington
60. Karalis K., Mastokaros G., Chrousos G.P., and Tolis G. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 93 (1994) 2000-2006
61. Fioravanti A., Govoni M., La Montagna G., Perpignano G., Tirri G., Trotta F., et al. Somatostatin-14 and joint inflammation: evidence for intra-articular efficacy of prolonged administration in rheumatoid arthritis. Drugs Exp Clin Res 21 (1995) 97-103
62. Barthó L., and Szolcsányi J. Opiate agonists inhibit neurogenic plasma extravasation in the rat. Eur J Pharmacol 73 (1981) 101-104
63. Xu X.J., Hao J.X., Wiesenfeld-Hallin Z.s., Hakanson R., Folkers K., Hökfelt T., et al. A novel tachykinin antagonist and galanin inhibit plasma extravasation induced by antidromic C-fibre stimulation in the rat hindpaw. Neuroscience 42 (1991) 731-737
64. Pintér E., Helyes Németh J., Oroszi G., and Szolcsányi J. Somatostatin, as anti-inflammatory neuromediator: in vivo and in vitro evidence. Naunyn-Schmiedeberg's Arch Pharmacol 356 Suppl. 1 (1997) R-44
65. Grant A. Leukocytes and neurogenic inflammation. Immunopharmacology 9 (2002) 403-420
66. Pincus T., Smith S., and Oates J.A. Somatostatin analogue octreotide is effective in revealing musculoskeletal pain associated with carcinoid syndrome. Arthritis Rheum 32 Suppl. 4 (1989) S71
67. Carlton S.M., Du Davidson J.E., Zhou S., and Coggeshall R.E. Somatostatin receptors on peripheral primary afferent terminals: inhibition on sensitised nociceptors. Pain 90 (2001) 233-244
68. Kéri G.y., Mezo{double acute} I., Vadász Z.s., Horváth A., Idei M., Vántus Á., et al. Structure-activity relationship studies of novel somatostatin analogs with antitumor activity. Pept Res 6 (1993) 281-288
69. Kéri G.y., Érchegyi J., Horváth A., Mezo{double acute} I., Idei M., Vántus T., et al. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo anti-tumor activity. Proc Natl Acad Sci USA 93 (1996) 12513-12518
70. Helyes Z.s., Pintér E., and Szolcsányi J. TT-232. Somatostatin sstr1/sstr4 agonist. Treatment of neuropathic pain. Treatment of inflammation. Drug Fut 30 (2005) 558-566
71. Helyes Z.s., Pintér E., Németh J., Kéri G.y., Thán M., Oroszi G., et al. Anti-inflammatory effect of synthetic somatostatin analogues in the rat. Br J Pharmacol 134 (2001) 1571-1579
72. Pintér E., Helyes Z.s., Németh J., Pórszász R., Petho{double acute} G., Thán M., et al. Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia. Naunyn-Schmiedeberg's Arch Pharmacol 366 (2002) 142-150
73. Schloos J., Raulf F., Hoyer D., and Bruns C. Identification and pharmacological. Characterization of somatostatin receptors in rat lung. Br J Pharmacol 121 (1997) 963-971
74. ten Bokum A.M.C., Lichtenauer-Kaligis E.G.R., Melief M.J., van Koetsveld P.M., Bruns C., van Hagen P.M., et al. Somatostatin receptor subtype. Expression in cells of the rat immune system during adjuvant arthritis. J Endocrinol 61 (1999) 167-175
75. Helyes Z.s., Pintér E., Szolcsányi J., and Horváth J. Anti-inflammatory and antinociceptive effect of different somatostatin analogs. Neurobiology 4 (1996) 115-117
76. Elekes K., Helyes Z.s., Kereskai L., Sándor K., Pintér E., Pozsgai G., et al. Inhibitory effects of synthetic somatostatin receptor subtype 4 agonists on acute and chronic airway inflammation and hyperreactivity in the mouse. Eur J Pharmacol 578 (2008) 313-322 :313-322
77. Engström M., Tomperi J., El Darwish K., Ahman M., Savola J.M., and Würster S. Superagonism at the human somatostatin receptor subtype 4. J Pharmacol Exp Ther 312 (2005) 332-338
78. Helyes Z.s., Pintér E., Németh J., Sándor K., Elekes K., Szabó Á., et al. Effects of the somatostatin receptor subtype 4 selective agonist J-2156 on sensory neuropeptide release and inflammatory reactions in rodents. Br J Pharmacol 149 (2006) 405-415
79. Berczi I., Chalmers I.M., Nagy E., and Warrington R.J. The immune effects of neuro-Peptides. Baillieres Clin Rheumatol 10 (1996) 227-257
80. Scholzen T., Amstrong C.A., Bunnett N.W., Luger T.A., Olerud J.E., and Ansel J.C. Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 7 (1998) 81-96
81. Sanake T., and Suzuki N. The role of somatostatin in the pathophysiology of rheumatoid arthritis. Clin Exp Rheumatol 16 (1998) 745-749